TransMedics Group, Inc.

TMDX · XNAS

CIK 1756262fmd_1BYJ444WHQBBQ9SXZA4Z8V5GB1Manufacturing · Electromedical & Electrotherapeutic ApparatusTemplate: Standard

Coverage: Jan 01, 2017 to Sep 30, 2026, 36 periods

Income Statement · Annual · Millions · USD
Line item	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Total revenues	–	13	24	26	30	93	242	442	605
Cost of revenue	–	7	10	9	9	28	88	179	243
Gross profit	–	6	14	17	21	65	154	262	363
Research and development	–	14	20	19	22	27	36	56	69
Selling, general and administrative	–	12	24	24	38	70	120	169	185
Total operating expenses	–	26	43	43	61	97	183	225	254
Operating income	–	(20)	(30)	(26)	(39)	(31)	(29)	37	109
Interest expense	–	3	4	4	4	4	11	14	14
Other non-operating income (expense)	–	(3)	(4)	(2)	(5)	(5)	2	(2)	(1)
Income before taxes	–	(24)	(34)	(29)	(44)	(36)	(27)	36	108
Income tax expense	0	0	0	0	–	0	(2)	0	(83)
Net income from continuing operations	–	(24)	(34)	(29)	–	(36)	(25)	35	190
Net income	–	(24)	(34)	(29)	(44)	(36)	(25)	35	190
Net income to common shareholders	–	–	–	–	–	–	(25)	35	198